Evaluating the Implementation of the ENDORISK Model for Personalized Lymph Node Risk Assessment in Early Stage Endometrial Cancer
Led by Radboud University Medical Center · Updated on 2026-07-29
735
Participants Needed
14
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of the ENDORISK Bayesian network model to improve preoperative risk assessment for lymph node metastasis in patients with early stage endometrial cancer. This study aims to see if implementing ENDORISK in everyday clinical practice enhances risk stratification compared to the current standard care. The study also looks at patient information sharing, treatment decisions, survival outcomes, quality of life, clinician experiences, and healthcare costs.
Participants are divided into two groups a control group receiving standard care based on prior data, and an intervention group using the ENDORISK model to receive personalized risk assessments and treatment plans including hysterectomy with or without lymph node surgery. The model is applied during preoperative counseling to guide treatment decisions. The study is conducted over several years in two oncology regions, with the intervention introduced sequentially.
During the study, participants will undergo lymph node staging if indicated, and complete questionnaires about information provision and shared decision-making up to 12 weeks after surgery. Researchers will monitor the proportion of patients choosing lymph node assessment, positive predictive value of detected metastases, survival rates over 5 years, health-related quality of life at 12 weeks and 12 months, treatment-related morbidity, clinician feedback, and regional care costs. The study starts in October 2025 and continues through October 2032.
CONDITIONS
Brief Title
Individualised Endometrial Cancer Risk Stratification by Bayesian Prediction Model (ENDORISK), Optimizing Clinical Implementation
Research Team
R
Ruben C.G. Koek, MD / Drs
H
Hanny M.A. Pijnenborg, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with early stage (FIGO stage I-II) endometrial carcinoma of any grade
Eligible for primary surgical treatment, including those receiving neo-adjuvant therapy
Able to understand Dutch or English
Able to complete digital or paper questionnaires
You will not qualify if you...
Unable to provide informed consent
Does not understand Dutch or English
Diagnosed with rare types of endometrial cancer, such as endometrial stroma cell sarcoma
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Intervention or Standard Care
Duration - From enrollment to surgery
Participants receive either standard care or personalized risk assessment and treatment planning using the ENDORISK model during preoperative counseling. Treatment plans include hysterectomy with or without lymph node surgery based on risk.
Treatment planning and counseling visits
Postoperative Follow-up
Duration - Up to 5 years after surgery
Participants complete questionnaires about information provision and shared decision-making up to 12 weeks after surgery. Longer-term outcomes such as survival, quality of life, and treatment-related morbidity are monitored for up to 5 years.
Questionnaire visits and medical assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Safety and Dosimetry Study of 177Lu-RAD204 Targeting PD-L1 in Patients With Selected Metastatic Solid Tumors
Study of 177LuBetaBart Monoclonal Antibody for Safety and Early Effects in Adults With Advanced Solid Tumors
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Study of Using 3D-Printed Custom Devices for High-Dose Radiation Treatment in Gynaecological Cancer
Phase III Trial Comparing BNT323 Versus Chemotherapy for HER2-Positive Recurrent Endometrial Cancer
Study on Cervical and Endometrial Cancer in Women Aged 20 to 75
Open-Label Phase 1 Trial Evaluating Safety and Activity of HH160 Alone or With Other Cancer Treatments in Adults With Advanced or Metastatic Solid Tumors
Study of CTIM-76, a Claudin-6 Directed Bispecific Antibody, in Adults With Platinum-Resistant Ovarian Cancer and Advanced Solid Tumors
Phase 1 Open-label Study of LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, Given Intravenously in Advanced Solid Tumors to Determine Safety and Recommended Dose
Phase 1a1b Study of NRM-823 Alone and With Immune Checkpoint Inhibitor in Advanced or Metastatic Refractory Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Improved preoperative risk stratification in endometrial carcinoma patients: external validation of the ENDORISK Bayesian network model in a large population-based case series.